Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-018-0093-4.pdf
Reference24 articles.
1. Hehlmann, R., Hochhaus, A., Baccarani, M. & European, L. Chronic myeloid leukaemia. Lancet 370, 342–350 (2007).
2. Jabbour, E. et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123, 494–500 (2014).
3. Fujisawa, S. et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up. Int. J. Hematol. 99, 141–153 (2014).
4. Hughes, T. P. et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123, 1353–1360 (2014).
5. Marin, D. et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30, 232–238 (2012).
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current Guidelines and Treatment Algorithm of Chronic Myeloid Leukemia;Pathogenesis and Treatment of Leukemia;2023
2. Molecular Response Assessment in Patients with Chronic Myeloid Leukemia; Clinicopathological Retrospective Research;Meandros Medical and Dental Journal;2022-12-29
3. Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels;Turkish Journal of Hematology;2022-08-24
4. Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells;Cancers;2021-11-18
5. MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response;Laboratory Medicine;2021-08-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3